{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:54:03Z","timestamp":1790132043133,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Cross\u2010resistance between different classes of anti\u2010neoplastic agents can jeopardize successful combination cancer chemotherapy. In this study, we observed an unexpected cross\u2010resistance between the podophyllotoxine derivative etoposide (VP) and the nucleoside analogue cladribine (CdA) in CCRF\u2010CEM cells developed for resistance to VP. The resistant cells also displayed 14\u2010 and twofold resistance to cytarabine (ara\u2010C) and gemcitabine respectively. Closer analysis of these cells showed that they contained lower amounts of topoisomerase (topo) II\u03b1 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001) and \u03b2 protein (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7026), formed substantially lower amounts of the topo II\u2013DNA complex, and had a markedly decreased level of Fas (CD95\/APO\u20101)\u2010ligand mRNA expression. Interestingly, Fas expression in the resistant cells did not differ from that in the parental cell line. No differences were observed in the accumulation\/efflux of daunorubicin or in the gene expressions of P\u2010glycoprotein, multidrug resistance\u2010associated protein and the lung resistance\u2010related protein. The activity of deoxycytidine kinase (dCK), responsible for activation of CdA and ara\u2010C, was the same for resistant and wild\u2010type cells. However, there was an increase in the activity of the cytosolic 5\u2032\u2010nucleotidases (5\u2032\u2010NT), responsible for deactivation of nucleotides, amounting to 206% (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001) for the high K<jats:sub>m<\/jats:sub> and 134% (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7331) for the low K<jats:sub>m<\/jats:sub> 5\u2032\u2010NT in resistant cells. The high K<jats:sub>m<\/jats:sub> 5\u2032\u2010NT is probably responsible for the decreased amount of the active metabolite CdA 5\u2032\u2010triphosphate [40% decreased (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7045)], as well as for other purine ribonucleosides and deoxyribonucleosides triphosphates in the resistant cells. In contrast, a significantly higher deoxycytidine triphosphate (dCTP) level (167%, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001) was observed in the resistant cells. Thus, this study suggests that the major cause of resistance to the nucleoside analogues CdA and ara\u2010C in cells selected for resistance to VP is a result of metabolic alterations producing increased activity of 5\u2032\u2010NT and higher dCTP levels. Furthermore, these results indicate that there is a common factor in the regulation of nucleotide\u2010degrading enzymes and DNA topoisomerases, which may be altered in cross\u2010resistant cells.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02751.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:27:39Z","timestamp":1027679259000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide"],"prefix":"10.1111","volume":"113","author":[{"given":"Kourosh","family":"Lotfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Knaust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Spasokoukotskaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Liliemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freidoun","family":"Albertioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09553008814552151"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","unstructured":"Beck W.T. Danks M.K. Wolverton J.S. Chen M. Granzen B. Kim R. Suttle D.P.(1994)Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.Advances in Pharmacology 296 145\u2013169.","DOI":"10.1016\/S1054-3589(08)61136-9"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.20.14255"},{"key":"e_1_2_6_5_1","first-page":"274","article-title":"Etoposide: an update","volume":"8","author":"Fleming R.A.","year":"1989","journal-title":"Clinical Pharmacology"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-574"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1493.bloodjournal8641493"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00063-X"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4681"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.1.29"},{"key":"e_1_2_6_11_1","first-page":"808","article-title":"Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1\u2010beta\u2010D\u2010 arabinofuranosylcytosine","volume":"9","author":"Grant S.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140351"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90034-O"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(96)90002-X"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.71"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210083271504"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.3.597.597"},{"key":"e_1_2_6_18_1","first-page":"124","article-title":"Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin","volume":"85","author":"Knaust E.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(98)00140-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199807000-00008"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01494.x"},{"key":"e_1_2_6_22_1","first-page":"2438","article-title":"Biochemical pharmacology and resistance to 2\u2010chloro\u20102\u2032\u2010arabino\u2010fluoro\u20102\u2032\u2010deoxyadenosine, a novel analogue of cladribine in human leukemic cells","volume":"5","author":"Lotfi K.","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/mol.55.2.216","article-title":"DNA damage signals induction of fas ligand in tumor cells","volume":"55","author":"Mo Y.Y.","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(83)91599-1"},{"key":"e_1_2_6_25_1","first-page":"5956","article-title":"Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line","volume":"59","author":"M\u00e5nsson E.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0396-297"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401649"},{"key":"e_1_2_6_28_1","first-page":"S67","article-title":"Pharmacology of purine nucleoside analogues","volume":"38","author":"Plunkett W.","year":"1996","journal-title":"Hematological Cell Therapy"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84334-0"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(96)00048-5"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb01409.x"},{"key":"e_1_2_6_32_1","first-page":"2021","article-title":"DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II","volume":"46","author":"Rowe T.C.","year":"1986","journal-title":"Cancer Research"},{"key":"e_1_2_6_33_1","first-page":"1223","article-title":"Lack of cross\u2010resistance with gemcitabine and cytarabine in cladribine\u2010resistant HL60 cells with elevated 5\u2032\u2010nucleotidase activity","volume":"26","author":"Schirmer M.","year":"1998","journal-title":"Experimental Hematology"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(89)90420-X"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00435-8"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-2584-4_142"},{"key":"e_1_2_6_37_1","first-page":"5528","article-title":"Expression of Fas\/APO\u20101 during the progression of astrocytomas","volume":"55","author":"Tachibana O.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_6_38_1","first-page":"3331","article-title":"Drug\u2010induced apoptosis is associated with enhanced Fas (Apo\u20101\/CD95) ligand expression but occurs independently of Fas (Apo\u20101\/CD95) signaling in human T\u2010acute lymphatic leukemia cells","volume":"57","author":"Villunger A.","year":"1997","journal-title":"Cancer Research"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.425963.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01353.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02906131"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02751.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02751.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02751.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T21:36:08Z","timestamp":1697578568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02751.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02751.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02751.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}